An esterase and its application in the preparation of chiral drug intermediates

By immobilizing recombinant esterases and using whole-cell catalysis, the efficiency and selectivity issues of esterase catalysts in the synthesis of dihydroergotamine intermediates were solved, achieving efficient and green chiral drug synthesis with a product optical purity of up to 99%, suitable for industrial production.

CN123063375APending Publication Date: 2026-11-10ZHEJIANG BOXIAO BIOPARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611547701.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-08
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

In the existing technology, esterase catalysts have low catalytic efficiency and weak stereoselectivity in the preparation of dihydroergotamine intermediates, which cannot meet the needs of industrial production and result in unstable optical purity of the product.

Method used

Using a recombinant esterase with an amino acid sequence as shown in SEQ ID NO.1, the synthesis of dihydroergotamine intermediates was achieved through immobilization or whole-cell catalysis, combined with codon optimization and expression in a specific vector.

Benefits of technology

It achieves efficient and green chiral drug synthesis with a product optical purity of up to 99%, simplifies the synthesis steps, is applicable to multiple production scenarios, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063375A_ABST
    Figure CN123063375A_ABST
Patent Text Reader

Abstract

This invention, entitled "An Esterase and Its Application in the Preparation of Chiral Drug Intermediates," belongs to the field of biocatalysis and drug synthesis technology. The technical problem to be solved is to develop a novel, efficient enzyme catalyst with high stereoselectivity to achieve low-cost, green chiral drug synthesis. The key technical point is that the esterase has the amino acid sequence shown in SEQ ID NO.1; this esterase can be used for the resolution and preparation of chiral drugs such as dihydroergotamine and S-flurbiprofen, achieving a conversion rate ≥99% and chiral selectivity ≥99%.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biocatalysis and drug synthesis technology, specifically relating to an esterase and its application in the preparation of chiral drug intermediates. Background Technology

[0002] Esterases (EC 3.1.1.3) are a class of enzymes that can hydrolyze or synthesize ester bonds, amide bonds, and carboxyl ester bonds. Currently, most industrially used esterases are derived from fungi, including *Aspergillus niger*, *Aspergillus flavus*, *Rhizopus*, *Geotrichum candida*, and yeasts. However, these natural enzymes have low content and low activity, making direct industrial production challenging. With the development of genetic engineering technology, the production of large quantities of esterases through heterologous expression has become crucial.

[0003] Dihydroergotamine is an important ergot alkaloid derivative widely used clinically to treat acute migraine attacks and prevent cluster headaches. Its pharmacological activity is highly dependent on the absolute configuration of multiple chiral centers in the molecule. Currently, industrial semi-synthetic routes typically use natural lysergic acid as a starting material, constructing the target molecule through multiple chemical reactions such as amidation and hydrogenation reduction. However, the hydrogenation step readily generates a pair of diastereomers, resulting in a mixture with insufficient optical purity, severely impacting the drug's bioavailability and safety.

[0004] Enzymatic synthesis has become a research hotspot in chiral drug synthesis due to its advantages such as mild reaction conditions, high stereoselectivity, and environmental friendliness. However, for products like dihydroergotamine, existing commercial enzymes exhibit extremely low catalytic efficiency and weak spatial recognition capabilities for specific sites, resulting in slow reaction rates and unstable product optical purity, making them unsuitable for industrial-scale production. Therefore, there is an urgent need to develop a novel, efficient, and highly stereoselective enzyme catalyst capable of specifically recognizing and converting the target isomer in the dihydroergotamine intermediate, thereby achieving low-cost and green chiral drug synthesis. Summary of the Invention

[0005] The purpose of this invention is to provide an esterase and related technologies to solve one or more technical problems in which existing technologies struggle to obtain novel, efficient, and highly stereoselective enzyme catalysts, and are unable to achieve chiral drug synthesis in a low-cost and green manner.

[0006] Terminology Explanation: Unless otherwise defined, all technical terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Unless otherwise stated, all patents, patent inventions, and publications cited throughout this document are incorporated herein by reference in their entirety. If multiple definitions exist for terms in this document, the definitions provided in this chapter shall prevail.

[0007] It should be understood that the above brief description and the following detailed description are exemplary and for illustrative purposes only, and do not limit the subject matter of the invention in any way. In this invention, the singular is used in conjunction with the plural unless otherwise specifically stated. It should also be noted that, unless otherwise stated, the use of “or” or “or” means “and / or”. Furthermore, the use of the term “comprising” and other forms such as “including,” “containing,” and “contains” are not limiting.

[0008] Definitions of standard chemical terms can be found in the textbook or reference book "Introduction to Enzymology and Enzyme Engineering", Tsinghua University Press, August 1, 2021.

[0009] Unless otherwise stated, conventional methods within the scope of the art, such as methods for detecting catalytic activity and chiral stereoselectivity, shall be used.

[0010] Unless specifically defined herein, the use of all commercially available products herein employs standard techniques. For example, it may be carried out using the manufacturer's instructions for use with the kit, or in accordance with methods known in the art or the description of this invention. The techniques and methods described herein can generally be implemented according to conventional methods well known in the art, based on the descriptions in the various summary and more specific documents cited and discussed in this specification.

[0011] All numerical values ​​or expressions relating to component amounts, process conditions, etc., used in this invention shall be understood to be modified by the word "about" in all cases. When referring to a quantity or range of values, the quantity or range is an approximation within experimental variability (or within statistical experimental error). In this invention, the term "about" shall have the meaning of being within 10%, preferably within 5%, of a specified value or range. Unless otherwise specified, percentages are mass percentages.

[0012] In this invention, "room temperature" refers to ambient temperature, ranging from about 15°C to about 37°C. In some embodiments, "room temperature" refers to a temperature ranging from about 20°C to about 30°C; in other embodiments, "room temperature" refers to a temperature ranging from about 25°C to about 30°C; and in still other embodiments, "room temperature" refers to 15°C, 20°C, 25°C, 30°C, 35°C, 37°C, etc.

[0013] Esterases (EC3.1.1.3) are a class of hydrolytic enzymes that can catalyze the hydrolysis or synthesis of ester bonds, amide bonds, and carboxyl ester bonds. In this invention, they specifically refer to recombinant esterases with amino acid sequences as shown in SEQ ID NO.1, which can stereoselectively hydrolyze ester substrates and are used for the biocatalytic synthesis of chiral drug intermediates.

[0014] Stereoselectivity refers to the ability of an enzyme to preferentially catalyze the formation of a product with a certain stereoconfiguration. In this invention, it refers to the esterase preferentially forming the target chiral product to achieve a high enantiomeric excess value.

[0015] Immobilized enzymes are enzyme preparations obtained by binding free enzymes onto a solid support through physical or chemical means. They retain the enzyme's catalytic activity and can be recycled and reused.

[0016] Whole-cell catalysis uses intact microbial cells expressing the target esterase as catalysts to directly transform substrates without disrupting the cells.

[0017] A carrier is a nucleic acid molecule that can carry inserted nucleic acid fragments into target cells.

[0018] Nucleic acid molecules refer to DNA molecules encoding the esterase of this invention, which can be obtained through codon optimization and used for vector construction.

[0019] Recombinant expression vectors, which are vectors into which target nucleic acid fragments are inserted through artificial gene manipulation, can achieve the transcription of target genes and the expression of proteins in host cells.

[0020] Microorganisms (host microorganisms), engineered bacteria capable of heterologously expressing the esterase of the present invention by introducing recombinant expression vectors.

[0021] Biological materials, including plant cell lines, plant tissues, plant organs, animal cell lines, animal tissues, or animal organs containing the recombinant expression vector of the present invention.

[0022] Codon optimization, without altering the amino acid sequence of the encoded protein, modifies the gene nucleotide sequence based on the codon preferences of the host microorganism to increase the expression level of the target protein.

[0023] IPTG, isopropyl-β-D-thiogalactoside, is an inducer used to initiate the expression of target gene proteins in pET vector systems.

[0024] SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) is used for the analysis of protein molecular weight and protein soluble expression.

[0025] Transformation is the process of introducing a recombinant vector into a prokaryotic host microbial cell to obtain a genetically engineered strain.

[0026] Bn: benzyl (-CH2Ph); Me: methyl (-CH3); Et: ethyl (-CH2CH3).

[0027] The alkyl groups described in this invention comprise saturated monovalent hydrocarbon groups having straight-chain, branched, or cyclic groups. For example, alkyl groups include methyl, ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclopentyl, n-hexyl, 2-hexyl, 2-methylpentyl, and cyclohexyl. Similarly, as in C...1-3 C in alkyl 1-3 It refers to a group containing 1, 2, or 3 carbon atoms arranged in a straight or branched form.

[0028] To achieve the above objectives, the present invention provides the following technical solution: In a first aspect, the present invention provides: an esterase having an amino acid sequence as shown in SEQ ID NO.1.

[0029] In some embodiments, the esterase has an amino acid sequence that differs from SEQ ID NO.1 by at least one amino acid.

[0030] In some implementations, the amino acid differences are achieved through the insertion, deletion, mutation, and / or modification of amino acids.

[0031] Secondly, the present invention provides: a nucleic acid molecule encoding the aforementioned esterase.

[0032] In some embodiments, the nucleic acid molecule has a nucleotide sequence as shown in SEQ ID NO.2.

[0033] Thirdly, the present invention provides a recombinant expression vector comprising the aforementioned nucleic acid molecules.

[0034] In some embodiments, the vector of the recombinant expression vector is selected from pET series expression vectors, pGEX vectors, pMAL vectors, pBAD vectors, or pACYC vectors.

[0035] Preferably, the vector is a pET series expression vector.

[0036] More preferably, the carrier is the pET-28a carrier.

[0037] Fourthly, the present invention provides: a microorganism comprising the aforementioned recombinant expression vector.

[0038] In some implementations, the microorganism is selected from Escherichia coli, Corynebacterium glutamicum, and Bacillus subtilis.

[0039] Preferably, the microorganism is selected from Escherichia coli.

[0040] More preferably, the microorganism is selected from Escherichia coli BL21(DE3), BL21(DE3)pLysS / pLysE, BL21 Star(DE3), Origami 2, Origami B, Shuffle T7, Rosetta(DE3), Rosetta-gami B(DE3) or C41(DE3).

[0041] More preferably, the microorganism is selected from BL21(DE3).

[0042] The microorganisms described in this invention can be obtained by transforming or transfecting host cells using the aforementioned recombinant expression vector. For example, it can be performed using the calcium chloride method (Journal of Molecular Biology (J.Mol.Biol.), Vol. 53, p. 159 (1970)), the Hanahan method (Journal of Molecular Biology, Vol. 166, p. 557 (1983)), the SEM method (Gene, Vol. 96, p. 23 (1990)), the method of Chung et al. (Proceedings of the National Academy of Sciences of the USA, Vol. 86, p. 2172 (1989)), the calcium phosphate co-precipitation method, electroporation (Potter, H. et al., Proc. Natl. Acad. Sci. USA 81, 7161-7165 (1984)), and lipid transfection (Felgner, P. et al., Proc. Natl. Acad. Sci. USA 84, 7413-7417 (1984)). It should be noted that the microorganisms of the present invention can be used to produce the aforementioned esterases of the present invention.

[0043] In some embodiments, the esterase may be selected from esterase-containing fermentation broth, centrifuged bacterial sludge, cell lysate, purified enzyme, or immobilized enzyme.

[0044] Fifthly, the present invention provides: a biological material having the aforementioned recombinant expression vector.

[0045] In some embodiments, the biomaterial is selected from plant cell lines, plant tissues, plant organs, animal cell lines, animal tissues, or animal organs.

[0046] In a sixth aspect, the present invention provides: an enzyme preparation comprising the aforementioned esterase.

[0047] In some embodiments, the enzyme agent further includes at least one of excipients, buffers, suspending agents, stabilizers, preservatives, and physiological saline.

[0048] In some embodiments, the excipient includes at least one selected from starch, dextrin, maltose, trehalose, lactose, D-glucose, sorbitol, D-mannitol, white sugar, and glycerol.

[0049] In some embodiments, the buffer includes at least one of phosphate, Tris-HCl, citrate, and acetate.

[0050] In some embodiments, the stabilizer includes at least one of propylene glycol and ascorbic acid.

[0051] In some embodiments, the preservative includes at least one of phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, and methylparaben.

[0052] In some embodiments, the preservative includes at least one of ethanol, benzalkonium chloride, p-hydroxybenzoic acid, and chlorobutanol.

[0053] In a seventh aspect, the present invention provides the use of the aforementioned esterase in the preparation of chiral drugs.

[0054] In some embodiments, the chiral drug is S-flurbiprofen.

[0055] In some embodiments, the chiral drug is a dihydroergotamine intermediate.

[0056] In some embodiments, the dihydroergotamine intermediate is a compound of formula (I): (I); Among them, R 1 Selected from H or Bn.

[0057] Eighthly, the present invention provides a method for preparing a chiral drug, comprising the following steps: (1) Ferment the aforementioned microorganisms and substrates to obtain a fermentation broth containing the target product; (2) The target product can be recovered from the fermentation broth obtained in step (1).

[0058] In some embodiments, when the chiral drug is S-flurbiprofen, the fermentation substrate in step (1) is a flurbiprofen carbon chain ester.

[0059] Furthermore, the flurbiprofen carbon chain ester is flurbiprofen-COO-R, wherein R is an alkyl group.

[0060] Preferably, the alkyl group is C1-C6. 12 Alkyl; more preferably C1-C 10 Alkyl; more preferably C1-C8 alkyl.

[0061] In some embodiments, when the chiral drug is a dihydroergotamine intermediate, the fermentation substrate in step (1) is a compound of formula (II): (II); Among them, R 1 Selected from H or Bn; R 2Selected from Me or Et.

[0062] In some embodiments, the dihydroergotamine intermediate is as described above.

[0063] In a ninth aspect, the present invention provides a chiral drug obtained by the above preparation method.

[0064] The present invention has at least the following beneficial effects: This invention uses esterases for chiral resolution, directly solving the problems of complex and costly chemical resolution processes in the synthesis of chiral drug intermediates. At the same time, all organic solvents are used in extremely small amounts, greatly simplifying the synthesis steps.

[0065] The esterases prepared in the embodiments of the present invention have extremely high activity and stereoselectivity, with chiral selectivity reaching over 99%.

[0066] This invention is applicable to multiple production scenarios, solves the problem of complex chiral separation steps in existing chiral drugs, and features mild reaction conditions, high optical purity, simple operation, and is environmentally friendly, making it more conducive to industrial production. Attached Figure Description

[0067] Figure 1 This is a schematic diagram of an esterase expression vector.

[0068] Figure 2 HPLC detection results for the preparation of dihydroergotamine intermediates catalyzed by esterase.

[0069] Figure 3 Chiral detection results for the preparation of dihydroergotamine intermediates catalyzed by esterase.

[0070] Figure 4 HPLC detection results for the preparation of S-flurbiprofen catalyzed by esterase.

[0071] Figure 5 Chiral detection results for the preparation of S-flurbiprofen catalyzed by esterase. Detailed Implementation

[0072] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0073] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all instruments, devices, equipment, reagents, products, etc., used in the embodiments of the present invention are obtained through conventional commercial means.

[0074] Unless otherwise specified in this invention, the temperature is room temperature and the percentage is a mass percentage.

[0075] The amino acid sequence shown in SEQ ID NO.1: MQIQGHYELR FEAVRETFAA LFDDPQERGA ALCIQVGGET VVDLWAGSAD KDGQQAWHSDTIANLFSCTK TFSAVTALQL VGEGKLTLDA PAANYWPEFA QAGKQAITLR QLLSHRAGLP AIRELLPAEALYDWQAMVDA LAAETPWWTP GTEHGYAAIT YGWLIGELIR RADGRGPGDS IVARTARPLG LDFHVGIADDEFYRVAHIAR GKGNAGDAAA QKLLQVTMRE PEALSTRAFT NPPAILTSTN KPEFRRMQQP AANGHGNARSLAGFYAGLLD GSLLESELLD ELTREHSLGQ DRTLLTQTRF GLGCMLDQPD VANATFGLGA RAFGHPGAGGSVGFADPEHD VAFGFVVNTL GPYVLMDPRA QKLVRVLASC L.

[0076] The nucleotide sequence shown in SEQ ID NO.2:

[0077] The dihydroergotamine substrate is a compound of formula (II), wherein R 1 For Bn, R 2 For Et, Preparation of dihydroergotamine substrate: Under nitrogen protection, diethyl 2-hydroxy-2-methylmalonate (10.0 g, 52.6 mmol; purchased from Maclean, catalog number: D760249) was dissolved in anhydrous DMF (100 mL). NaH (2.52 g, 63.1 mmol) was added in portions at 0 °C. After stirring at room temperature for 1 hour, benzyl bromide (10.8 g, 63.1 mmol) was added dropwise, and the reaction was allowed to proceed for 12 hours. The reaction was quenched with saturated NH4Cl aqueous solution, extracted with ethyl acetate, washed with water and saturated brine, dried, concentrated, and purified by silica gel column chromatography (PE / EA = 10:1) to give a colorless oily product (12.8 g, yield 87%).

[0078] Dihydroergotamine substrate: ; 1 H NMR (400 MHz, DMSO- d 6) δ = 7.38–7.29 (m, 5H), 4.58 (s, 2H), 4.21(q, J = 7.1 Hz, 4H), 1.64 (s, 3H), 1.22 (t, J = 7.1 Hz, 6H). MS: C 15 H 20 O5m / z calcd 280.1, found 281.2. Preparation of flurbiprofen carbon chain esters: 50 g flurbiprofen and 100 mL C1-C8 alcohol were added to a 500 mL dry reaction flask and stirred to dissolve. 32 g thionyl chloride was added dropwise at 15-25 °C. After the addition was complete, the reaction was carried out at 15-25 °C for 12-18 h. The reaction of the starting material was monitored by TLC (petroleum ether: ethyl acetate = 5:1, v / v) to ensure complete reaction. The mixture was concentrated under reduced pressure to remove excess alcohol and thionyl chloride, yielding a yellow oily substance. 200 mL ethyl acetate and 100 mL water were added, and the mixture was stirred and extracted for 10 min. The layers were separated, the aqueous phase was discarded, and the organic phase was washed once with 50 mL 10% saline solution. The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a colorless or pale yellow oily liquid. The molar yield of the product was 85-92%.

[0079] Flurbiprofen methyl ester: ¹H NMR (400 MHz, CDCl3)δ7.56 – 7.12 (m, 8H), 3.77(q, J = 7.2 Hz, 1H),3.71 (s, 3H), 1.54 (d, J = 7.2 Hz, 3H).MS: C 16 H 15 FO2m / z calcd 258.29, found259.1. Flurbiprofen ethyl ester: ¹H NMR (400 MHz, CDCl3) δ7.56–7.13 (m, 8H), 4.22–4.13 (m, 2H), 3.78–3.73 (m, 1H), 1.56–1.54 (d, J = 7.2 Hz, 3H), 1.28–1.24 (t, J = 7.2 Hz, 3H).MS: C 17 H 17 FO2m / z calcd 272.31, found 273.1. Flurbiprofen propyl ester: ¹H NMR (400 MHz, CDCl3)δ 7.54 – 7.07 (m, 8H), 4.07 (t, J = 6.7 Hz, 2H), 3.76 (q, J = 7.2 Hz, 1H), 1.65 (p, J = 7.1 Hz, 2H), 1.54 (d, J = 7.2 Hz, 3H), 0.90(t, J = 7.4 Hz, 3H). MS: C 18 H 19 FO2m / z calcd 286.34, found 287.1. Flurbiprofen isopropyl ester: ¹H NMR (400 MHz, CDCl3)δ 7.61 – 7.05 (m, 8H), 5.03 (hept, J = 6.3 Hz, 1H), 3.71 (q, J = 7.2 Hz, 1H), 1.53 (d, J = 7.2 Hz, 3H), 1.26 (d, J = 6.3 Hz, 3H), 1.19 (d, J= 6.2 Hz, 3H). MS: C 18 H 19 FO2m / z calcd 286.34, found 286.1. Flurbiprofen n-butyl ester: ¹H NMR (400 MHz, CDCl3)δ 7.58 – 7.12 (m, 8H), 4.11 (t, J = 6.7 Hz, 2H), 3.75 (q, J = 7.1 Hz, 1H), 1.65 – 1.51 (m, 5H), 1.32 (dp, J = 16.3, 7.9 Hz, 2H), 0.90 (t, J = 7.3 Hz, 3H). MS: C 19 H 21 FO2m / z calcd 300.37, found 301.2. Flurbiprofen n-amyl ester: 1 H NMR (400 MHz, CDCl3)δ 8.20 – 7.01 (m, 8H), 4.21 (t, J = 6.7 Hz, 2H), 3.86 (q, J = 7.2 Hz, 1H), 1.72 (q, J = 6.9 Hz, 2H), 1.65 (d, J = 7.1 Hz, 3H), 1.39(s, 5H), 0.99 (t, J = 6.7 Hz, 3H). MS: C 20 H 23 FO2m / z calcd 314.39, found 315.2. Fermentation medium: containing 12 g / L soybean peptone, 24 g / L industrial-grade yeast peptone, 12.54 g / L dipotassium hydrogen phosphate (purchased from Sinopharm), 5.3 g / L potassium dihydrogen phosphate (purchased from Sinopharm), 5-10 g / L glycerol (purchased from Sinopharm), and 0.01% antifoaming agent for microbial fermentation (purchased from Meilun Biotechnology).

[0080] IPTG inducer, purchased from Solarbio, product number: I8070.

[0081] Example 1 Construction of esterase strain After codon optimization, the target esterase was synthesized by Genewiz, and NdeI and BamHI restriction sites were designed at both ends of the gene. The gene was then cloned into the corresponding sites of the expression vector pET-28a. Figure 1 The recombinant plasmid obtained was transformed into Escherichia coli host cell BL21(DE3) to obtain the esterase strain, which was then stored at -80℃.

[0082] Example 2 Preparation of esterase The esterase strain was streaked on LB agar plates containing 30 μg / mL kanamycin and incubated overnight at 37°C until single colonies grew.

[0083] Single clones were inoculated into LB liquid medium containing 50 μg / mL kanamycin and cultured overnight at 37°C and 200 rpm. The culture was then inoculated at a 2% inoculum into a 5L fermenter containing 2.5 L of fermentation medium, and the temperature was controlled at approximately 37°C, pH approximately 6.8-7.4, and dissolved oxygen ≥20%.

[0084] After the dissolved oxygen rebounds, 66% glucose solution is added at a rate of 12-18 mL / h / L for feeding; when the OD600 reaches about 30, the temperature is lowered to 25℃, and IPTG inducer with a final concentration of 0.2 mM is added for induction expression at 25℃ for 20 h to obtain the fermentation broth containing esterase.

[0085] Example 3 Preparation of esterase The difference between this embodiment and Embodiment 2 is that a solid-liquid separation step is added. Specifically: Centrifuge the fermentation broth at 8000 rpm for 10-15 min and collect the bacterial cells containing esterase.

[0086] Example 4 Preparation of esterase The difference between this embodiment and Embodiment 3 is that a pyrolysis step is added. Specifically: The preparation of the esterase may further include the following steps: adding lysis buffer to the bacterial cells to obtain a lysis buffer containing the esterase.

[0087] Example 5 Preparation of esterase The difference between this embodiment and Embodiment 4 is the addition of a purification step. Specifically: The preparation of the esterase may further include the following steps: purifying the lysate to obtain the esterase.

[0088] Example 6: Preparation of dihydroergotamine intermediate by esterase catalysis After codon optimization, the target esterase was synthesized by Genewiz, and NdeI and BamHI restriction sites were designed at both ends of the gene before cloning into the corresponding sites of the expression vector pET-28a. Figure 1 The recombinant plasmid obtained was transformed into Escherichia coli host cell BL21(DE3) to obtain the esterase strain, which was then stored at -80℃.

[0089] The preserved strain was streaked onto LB agar plates containing 30 ug / mL kanamycin and incubated overnight at 37°C until single colonies grew.

[0090] Single clones were inoculated into LB liquid medium containing 50 μg / mL kanamycin and cultured overnight at 37°C and 200 rpm. The culture was then inoculated at a 2% inoculum into a 5L fermenter containing 2.5 L of fermentation medium, and the temperature was controlled at approximately 37°C, pH approximately 6.8-7.4, and dissolved oxygen ≥20%.

[0091] After the dissolved oxygen rebounds, 66% glucose solution is added at a rate of 12-18 mL / h / L for feeding; when the OD600 reaches about 30, the temperature is lowered to 25℃, and IPTG inducer with a final concentration of 0.2 mM is added for induction of expression.

[0092] Six hours after the start of IPTG-induced expression, 200 mL of dihydroergotamine substrate was added to the fermenter, while the 66% glucose feed rate was reduced to 6-12 mL / h / L until fermentation was complete. During the experiment, samples were taken at fixed points and the changes in substrate and product were monitored by HPLC. The reaction was stopped when the product concentration no longer increased.

[0093] Example 7 Extraction of dihydroergotamine intermediate The fermentation broth from Example 6 was centrifuged to obtain the supernatant, and the bacterial sludge was washed with pure water. The supernatants from the two centrifugations were combined and ultrafiltered through a 3kDa ultrafiltration membrane to collect the permeate.

[0094] Unreacted substrate in the liquid was removed by extraction with ethyl acetate.

[0095] Collect the aqueous phase and adjust the pH to 3-4 with sodium citrate monohydrate. Add an equal volume of ethyl acetate and extract again. Repeat twice and combine the organic phases.

[0096] Add an appropriate amount of anhydrous sodium sulfate to the organic phase and filter to obtain the crude product liquid.

[0097] The crude product was concentrated under reduced pressure (temperature 45℃, vacuum degree P≤-0.08MPa) until the volume no longer decreased, thus obtaining the crude oily dihydroergotamine intermediate. The HPLC detection results of the dihydroergotamine intermediate are as follows: Figure 2 As shown, the chiral detection results are as follows: Figure 3 As shown.

[0098] Example 8: Esterase-catalyzed preparation of S-flurbiprofen After codon optimization, the target esterase was synthesized by Genewiz, and NdeI and BamHI restriction sites were designed at both ends of the gene before cloning into the corresponding sites of the expression vector pET-28a. Figure 1 The recombinant plasmid obtained was transformed into Escherichia coli host cell BL21(DE3) to obtain the esterase strain, which was then stored at -80℃.

[0099] The preserved strain was streaked onto LB agar plates containing 30 ug / mL kanamycin and incubated overnight at 37°C until single colonies grew.

[0100] Single clones were inoculated into LB liquid medium containing 50 μg / mL kanamycin and cultured overnight at 37°C and 200 rpm. The culture was then inoculated at a 2% inoculation rate into a 5L fermenter containing 2.5L of fermentation medium, and the temperature was controlled at approximately 37°C, pH approximately 6.8-7.4, and dissolved oxygen ≥20%.

[0101] After the dissolved oxygen rebounds, 66% glucose solution is added at a rate of 12-18 mL / h / L for feeding; when the OD600 reaches about 30, the temperature is lowered to 25℃, and IPTG inducer with a final concentration of 0.2 mM is added for induction of expression.

[0102] Six hours after the start of IPTG-induced expression, 50 mL of flurbiprofen carbon chain ester was added to the fermenter as a substrate, while the 66% glucose feed rate was reduced to 6-12 mL / h / L until fermentation was complete. During the experiment, samples were taken at fixed points and the changes in substrate and product were monitored by HPLC. The reaction was stopped when the product concentration no longer increased.

[0103] The fermentation broth was centrifuged, washed, and membrane-coated to obtain a clear solution containing S-flurbiprofen. After extraction with ethyl acetate and back-extraction with an alkaline solution, HCl was added to the aqueous phase to adjust the pH to 1-2, resulting in the precipitation of a large amount of crystals. After filtration, rinsing, and drying, S-flurbiprofen was obtained. The HPLC detection results of S-flurbiprofen are as follows: Figure 4 As shown, the chiral detection results are as follows: Figure 5 As shown.

[0104] The conversion rate and chirality of flurbiprofen carbon chain esters catalyzed by esterases are shown in Table 1.

[0105] Table 1

[0106] As shown in Table 1, when the esterase of the present invention catalyzes the chiral resolution of flurbiprofen carbon chain esters, the enantiomeric excess value (ee) is... pThe percentages are all not less than 95%. This indicates that the esterase of the present invention has high catalytic activity and extremely high stereoselectivity for flurbiprofen carbon chain esters, and can efficiently and selectively prepare S-flurbiprofen.

[0107] Comparative Example 1 The only difference between this comparative example and Example 8 is the esterase.

[0108] Specifically, the esterase used in this comparative study was derived from Candida antarcticis (Candida). Candida antarctica The esterase of CALB (PDB number: 4K6G) was codon-optimized, and a recombinant strain was constructed and expressed. Flurbiprofen carbon chain esters were fed-through using the same process, followed by chiral resolution of the substrate. The results are shown in Table 2.

[0109] Table 2

[0110] As shown in Table 2, when Comparative Example 1 used CALB esterase to catalyze the carbon chain esterification of flurbiprofen, the conversion rates (Conv) were all low (below 8%), and the enantiomeric excess values ​​(ee) were also low. p The catalytic activity and stereoselectivity of the enzyme were also significantly lower (the highest being only 56.44%), and its catalytic activity and stereoselectivity were significantly inferior to those of the esterase of the present invention.

[0111] Comparative Example 2 The only difference between this comparative example and Example 8 is the esterase.

[0112] Specifically, the esterase used in this comparative study is derived from Serratia marcescens (Serratia marcescens). Serratia marcescens The esterase of esf (UniProt ID: Q0MVP2) was codon-optimized, and a recombinant strain was constructed and expressed. Flurbiprofen carbon chain esters were fed into the strain using the same process, followed by chiral resolution of the substrate. The results are shown in Table 3.

[0113] Table 3

[0114] Note: "-" in the table indicates that it was not detected.

[0115] As shown in Table 3, when Comparative Example 2 used ESF esterase to catalyze flurbiprofen carbon chain esters, it only had certain catalytic activity for short-chain esters such as flurbiprofen methyl ester, ethyl ester, and propyl ester, and the overall conversion rate (Conv) was low (the highest being only 13.03%). It had almost no catalytic activity for branched or long-chain esters such as flurbiprofen isopropyl ester, n-butyl ester, and n-pentyl ester. This indicates that the substrate adaptability and catalytic activity of ESF esterase are significantly inferior to those of the esterase of this invention.

[0116] In summary, this invention provides an esterase with the amino acid sequence shown in SEQ ID NO.1. This esterase can be used for the resolution and preparation of chiral drugs such as dihydroergotamine intermediates and S-flurbiprofen. The method for preparing chiral drugs using the esterase described in this invention has advantages such as simple operation, high product yield, and high optical purity. Furthermore, the process is green and environmentally friendly, making it more suitable for industrial production. This method is of great significance for the industrial production of chiral drugs such as dihydroergotamine intermediates and S-flurbiprofen.

[0117] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. An esterase, characterized in that, It has the amino acid sequence shown in SEQ ID NO.

1.

2. A nucleic acid molecule, characterized in that, Encoding the esterase as described in claim 1.

3. The nucleic acid molecule according to claim 2, characterized in that, The nucleic acid molecule has a nucleotide sequence as shown in SEQ ID NO.

2.

4. A recombinant expression vector, characterized in that, It includes the nucleic acid molecule as described in claim 2 or 3.

5. A microorganism, characterized in that, It includes the recombinant expression vector as described in claim 4.

6. A biomaterial, characterized in that, It includes the recombinant expression vector of claim 4; the biological material is selected from plant cell lines, plant tissues, plant organs, animal cell lines, animal tissues or animal organs.

7. An enzyme agent, characterized in that, It includes the esterase described in claim 1.

8. The use of the esterase according to claim 1 in the preparation of chiral drugs, characterized in that, The chiral drug is an intermediate of S-flurbiprofen or dihydroergotamine; The dihydroergotamine intermediate is the compound shown in formula (I): (I); Among them, R 1 Selected from H or Bn.

9. A method for preparing a chiral drug, characterized in that, Includes the following steps: (1) Ferment the microorganisms and substrate described in claim 5 to obtain a fermentation broth containing the target product; (2) The target product can be recovered from the fermentation broth obtained in step (1); When the chiral drug is S-flurbiprofen, the fermentation substrate in step (1) is flurbiprofen carbon chain ester; The flurbiprofen carbon chain ester is flurbiprofen-COO-R, wherein R is an alkyl group; When the chiral drug is a dihydroergotamine intermediate, the fermentation substrate in step (1) is the compound represented by formula (II): (II); Among them, R 1 Selected from H or Bn; R 2 Selected from Me or Et; The dihydroergotamine intermediate is the compound shown in formula (I): (I); Among them, R 1 Selected from H or Bn.

10. The chiral drug prepared by the method of claim 9.